Special Issue

Advanced Research on Radioresistant Tumors

Message from the Guest Editors

Radioresistant tumors pose a critical challenge in oncology, often resulting in poor patient outcomes despite ongoing advancements in therapeutic modalities. The aim of this Special Issue, titled "Advanced Research on Radioresistant Tumors", is to provide a comprehensive platform for understanding and overcoming radioresistance, with a focus on the latest advancements in radiotherapy, immunotherapy, chemotherapy, and genetic research. By covering cutting-edge developments in radiotherapy techniques such as proton and heavy ion therapy, exploring novel genetic findings, and discussing the integration of immunomodulatory strategies, this Issue will offer valuable insights into overcoming treatment barriers and enhancing therapeutic efficacy. Our objective is to collect a diverse range of articles that not only drive innovation but also serve as a practical guide for clinicians and experts in the field. We aim to create a resource that clinicians can utilize in clinical settings, showcasing the latest findings in specific cancers, highlighting the latest treatment possibilities, and presenting novel ideas for tackling radioresistance.

Guest Editors

Dr. Mansoor M. Ahmed

Division of Radiation Biology and Molecular Therapeutics, Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, USA

Dr. Kamila Rawojć

Maria Sklodowska-Curie Institute of Oncology, Cracow, Poland

Deadline for manuscript submissions

30 September 2025



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/219801

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

